Annexin Pharmaceuticals AB (publ)

Annexin Pharmaceuticals maintains a strong liquidity position, with a current ratio of 7.39, indicating that the company has sufficient current assets to cover its current liabilities multiple times over. The company has no long-term debt, and its debt-to-equity ratio is 0.0, reflecting a conservative capital structure with no leverage. The price-to-book ratio of 1.05 suggests that the company's market value is closely aligned with its book value, indicating a relatively stable valuation. The company's profitability metrics are currently negative, with a return on equity of -40.28% and a return on assets of -35.05%, reflecting ongoing losses and a lack of asset efficiency. These figures are below the typical performance of the biotechnology and medical research industry, where positive returns are often a key indicator of value creation. The operating and net losses of -14.46 million SEK and -14.51 million SEK, respectively, underscore the company's current financial challenges. Annexin Pharmaceuticals' revenue concentration is not disclosed in the available data, but the absence of disclosed segments or geographic breakdowns suggests that the company may be in an early stage of development or may not have material operations outside of its core business. This lack of diversification could pose a risk if the company's primary therapeutic area faces regulatory or market setbacks. The company's growth trajectory is uncertain, as there is no disclosed revenue history to assess trends. The absence of capital expenditures and the negative operating and free cash flows indicate that the company is likely in a research and development phase, with no significant revenue-generating operations yet. Analysts have provided a single price target of 75.00 SEK, which is significantly higher than the current market price of 5.37 SEK, suggesting potential upside if the company achieves key milestones. The risk assessment for Annexin Pharmaceuticals indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company's low dilution risk is supported by the fact that basic and diluted shares outstanding are equal, and there is no indication of near-term equity issuance. However, the company's ongoing losses and lack of revenue could increase the likelihood of future dilution if additional capital is required to fund operations. Recent events for Annexin Pharmaceuticals include the publication of its latest financial data, which shows continued losses and no revenue generation. The company has not disclosed any recent filings or transcripts that would provide insight into its strategic direction or operational progress. Analysts have not provided detailed commentary on the company's near-term prospects, but the high price target suggests optimism about its long-term potential.